Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
| ▸ | PTGIR | P43119 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20463210 | 0.90 | MTNR1A (0.55) | PPARAPPARGLMNAMTNR1AMTNR1B | |
| SCHEMBL2769878 | 0.89 | PPARA (0.63) | PPARAPPARGLMNAALDH1A1PTGDR2 | |
| SCHEMBL4587671 | 0.88 | SMN1; SMN2 (0.57) | LMNAALDH1A1POLBSMN1; SMN2PLAAT3 | |
| SCHEMBL10063439 | 0.86 | MTNR1A (0.54) | PPARAPPARGLMNAMTNR1AMTNR1B | |
| SCHEMBL23193815 | 0.84 | PPARA (0.58) | PPARAPPARGLMNAPTGDR2PTGIR | |
| SCHEMBL2769640 | 0.84 | MTNR1A (0.50) | PPARAPPARGLMNAMTNR1AMTNR1B | |
| SCHEMBL23193851 | 0.84 | LTA4H (0.46) | PPARAPPARGLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL24782143 | 0.83 | ALDH1A1 (0.58) | LMNAMTNR1AMTNR1BALDH1A1POLB | |
| SCHEMBL2769715 | 0.83 | PPARA (0.74) | PPARAPPARGLMNAPTGDR2PTGIR | |
| SCHEMBL2768776 | 0.83 | LMNA (0.52) | PPARAPPARGLMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200308144-A1 | Multimeric piperidine derivatives | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-10-01 | — | — | US | disclosed |
| WO-2020163594-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010077317-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010065110-A2 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-0776327-B1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | PPARA 4812/4885PPARG 4748/4885LMNA 800/4885 |
| US-20200308144-A1 | Multimeric piperidine derivatives | FKBP14, FKBP5, FKBP3 | PPARA 1390/4885PPARG 2359/4885LMNA 3984/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | PPARA 4156/4885PPARG 3704/4885LMNA 3392/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | PPARA 4253/4885PPARG 3830/4885LMNA 3381/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | PPARA 3666/4885PPARG 3733/4885LMNA 3678/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | PPARA 4414/4885PPARG 3958/4885LMNA 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.